05
OCT
2020
Northwest Biotherapeutics Announces Data Lock of Phase III Trial
Comments : Off
FOR IMMEDIATE RELEASE CONTACTS Dave Innes 804-513-4758 dinnes@nwbio.com Les Goldman 240-234-0059 lgoldman@nwbio.com BETHESDA, Md., October 5, 2020 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked. With the database now locked, the... Read More